Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study
Table 2
Patient baseline and demographic characteristics.
Free-dose combination group
= 293
Fixed-dose combination group
= 366
Total
= 659
Age, years
62.0 (9.6)
61.9 (8.7)
61.9 (9.1)
60–75, (%)
141 (48.1)
192 (52.5)
334 (50.5)
>75, (%)
23 (7.8)
16 (4.4)
39 (5.9)
Gender, men, (%)
152 (51.9)
205 (56.0)
360 (54.4)
Body mass index, kg/m2
29.6 (3.9)
30.4 (4.04)
30.1 (4.0)
Duration of T2DM, months
55.4 (51.1)
62.4 (55.2)
59.6 (54.2)
Mean HbA1c, %
7.9 (0.8)
8.1 (0.9)
8.0 (0.8)
Comorbidity, yes, (%)
54 (18.4)
49 (13.4)
104 (15.7)
Concomitant treatments, yes, (%)
28 (9.6)
31 (8.5)
60 (9.1)
T2DM, type 2 diabetes mellitus; data are presented as mean (SD) unless otherwise specified.
